The mechanism of action of most approved drugs in use today is based on their binding to
specific proteins or DNA. One of the achievements of this research is a new perspective for …

A series of calculations employing hybrid quantum mechanics/molecular mechanics
methods to explore the binding of square-planar complexes to fragments of DNA are …

Two new platinum (II) complexes,[Pt (bpy)(pip)](NO 3) 2 (1) and [Pt (bpy)(hpip)](NO 3) 2· 2H
2 O (2)(bpy is 2, 2′-bypyridine; pip is 2-phenylimidazo [4, 5-f][1, 10] phenanthroline; hpip is …

Two new mono-nuclear heteroleptic platinum (II) complexes,[Pt (bpy)(iip)](PF 6) 2 (1) and [Pt
(bpy)(miip)](PF 6) 2· 2H 2 O (2)(bpy is 2, 2′-bipyridine; iip is 2-(imidazo-4-yl)-1 H-imidazo …

A new mononuclear Pt (II) complex,[Pt (DMP)(DIP)] Cl2. H2O, in which DMP is 4, 4‐dimethyl‐
2, 2‐bipyridine and DIP is 4, 7‐diphenyl‐1, 10‐phenantroline, has been synthesized and …

Platinum anticancer drugs inhibit the division of cancer cells through a DNA binding
mechanism. The bimetallic platinum compounds have a possibility for blocking DNA …

Platinum-based drugs are widely recognized efficient anti-tumor agents, but faced with
multiple undesirable effects. Here, four dinuclear platinum (II) complexes,[{Pt (1, 2-pn) Cl} 2 …

In the search for novel platinum-based anticancer therapeutic agents, we have recently
established a structural motif of (O, S) bidentate ligands bound to a Pt (II) metal center which …

This review summarizes studies on substitution-inert polynuclear platinum complexes
(PPCs) which bind to DNA through the phosphate clamp–a discrete mode of DNA–ligand …

A series of platinum (II) complexes of the type [Pt (NN)(pyB) 2](NO3) 2 (NN= bipy, phen;
pyB= 3-or 4-pyridineboronic acid) were successfully prepared and fully characterised by 1D …